⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CLDX News
Celldex Therapeutics, Inc
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
globenewswire.com
CLDX
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
globenewswire.com
CLDX
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at
globenewswire.com
CLDX
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at
globenewswire.com
CLDX
Form 8-K
sec.gov
CLDX
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
globenewswire.com
CLDX
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
globenewswire.com
CLDX
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
globenewswire.com
CLDX
BioNJ Elects Board Officers and Trustees
prnewswire.com
GMAB
MRK
AMTX
JNJ
ASND
ACAD
BMY
PFE
PTC
NVS
SNY
CLDX
Celldex to Present at Upcoming Investor Conferences
globenewswire.com
CLDX